Study guide

9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease

Key Takeaways Explain This Topic AI

Giant Cell Arteritis (GCA) is a medical emergency requiring immediate high-dose systemic corticosteroid therapy prior to temporal artery biopsy to prevent permanent visual loss.

Status epilepticus is defined as continuous seizure activity lasting >5 minutes; emergency initial treatment requires prompt administration of IV lorazepam or IM midazolam.

Parkinson's disease presents with asymmetric resting tremor, cogwheel rigidity, bradykinesia, and postural instability, treated primarily with levodopa/carbidopa.

Myasthenia gravis causes fatigable muscle weakness worse with exertion; diagnostic workup includes AChR antibodies and ice pack test, while myasthenic crisis requires IVIG or plasma exchange.

Guillain-Barré syndrome presents with progressive ascending flaccid paralysis and areflexia following an infection, with lumbar puncture showing albuminocytologic dissociation.

Last updated: July 2026

Approach to Headaches & Red Flag Features

Headaches represent one of the most common neurological complaints in primary care and emergency medicine. The critical first step is distinguishing primary headache disorders (migraine, tension-type, cluster) from life-threatening secondary headache causes.

Red Flag Features: The SNOOP4 Criteria

The presence of any SNOOP4 red flag requires immediate neuroimaging (CT or MRI) and diagnostic workup:

S ystemic symptoms (fever, weight loss, night sweats, malignancy history).

N eurological signs or focal deficits (papilledema, confusion, seizures, cranial nerve palsy).

O nset sudden or explosive ("thunderclap" headache reaching peak intensity in < 1 minute <1\text{ minute} < 1 minute ).

O lder age at onset (new headache presentation in patients > 50 >50 > 50 years of age).

P attern change, P ositional headache (worse lying flat or standing), P apilledema, or P recipitated by Valsalva/coughing.

Primary Headache Syndromes

  • Feature Migraine Tension-Type Cluster Headache
  • Location Unilateral (60%) or bilateral Bilateral ("band-like") Strictly Unilateral (Orbital/Periorbital)
  • Quality Pulsating, throbbing Dull, aching, pressure Severe, sharp, searing, "boring"
  • Duration 4 to 72 hours 30 minutes to 7 days 15 to 180 minutes

Associated Signs Nausea, vomiting, photophobia, phonophobia, aura (20%) None (no severe nausea or photophobia) Ipsilateral lacrimation, rhinorrhea, nasal congestion, Horner syndrome, extreme restlessness

Acute Treatment NSAIDs, Triptans (Sumatriptan), Acetaminophen NSAIDs, Acetaminophen 100% High-Flow Oxygen ( 12 – 15 L/min 12\text{--}15\text{ L/min} 12 – 15 L/min ) + SC Sumatriptan

Prophylaxis Beta-blockers (Propranolol), Topiramate, Amitriptyline, CGRP inhibitors Amitriptyline Verapamil

Exam Trap: Triptans (e.g., sumatriptan) are potent 5-HT1B/1D receptor agonists that cause coronary vasoconstriction. They are strictly contraindicated in patients with ischemic heart disease, previous MI, uncontrolled hypertension, peripheral vascular disease, or cerebrovascular disease.

Giant Cell Arteritis (Temporal Arteritis)

Giant Cell Arteritis (GCA) is a granulomatous vasculitis of medium and large arteries, predominantly affecting the extracranial branches of the carotid artery in patients > 50 >50 > 50 years old.

Clinical Presentation: New localized headache, scalp tenderness (pain when combing hair), jaw claudication (pain in masseter muscles while chewing, highly specific), polymyalgia rheumatica symptoms (proximal shoulder/hip stiffness), and visual disturbances (amaurosis fugax or sudden painless monocular vision loss due to anterior ischemic optic neuropathy).

Laboratory Findings: Markedly elevated ESR ( > 50 mm/h >50\text{ mm/h} > 50 mm/h , often > 100 mm/h >100\text{ mm/h} > 100 mm/h ) and elevated CRP.

Management Rule: If GCA with visual symptoms is suspected, initiate high-dose systemic corticosteroids immediately (IV Methylprednisolone 1 g/day 1\text{ g/day} 1 g/day for 3 days or oral Prednisone 60 mg/day 60\text{ mg/day} 60 mg/day ) BEFORE obtaining a temporal artery biopsy. Do NOT delay steroid therapy for biopsy or specialist evaluation, as visual loss can become permanent within hours.

Seizures & Status Epilepticus Management

Seizures result from abnormal, excessive, hypersynchronous neuronal activity in the brain. They are classified as focal (originating within one hemisphere) or generalized (simultaneously engaging both hemispheres).

First Unprovoked Seizure Workup

Serum electrolytes, blood glucose, calcium, magnesium, renal and liver function tests.

Toxicology screen and anti-seizure medication levels (if previously diagnosed).

Electroencephalogram (EEG) to assess epileptiform activity.

Brain MRI (preferred over CT) to rule out structural lesions (tumor, vascular malformation, stroke, cortical dysplasia).

Status Epilepticus Emergency Protocol

Status epilepticus is defined as continuous seizure activity lasting > 5 minutes >5\text{ minutes} > 5 minutes , or ≥ 2 \ge 2 ≥ 2 discrete seizures without full neurological recovery between episodes. Neuronal injury begins after 5 minutes of continuous seizure. [Time 0-5 min]: Initial Assessment & Stabilization

  • ├─ Maintain airway, suction, apply 100% O2
  • ├─ Check capillary blood glucose (if < 2.8 mmol/L -> give D50W IV)
  • └─ Establish IV access, continuous ECG and pulse oximetry
  • [Time 5-20 min]: First-Line Emergent Therapy (Benzodiazepines)
  • ├─ Lorazepam 4 mg IV over 2 min (repeat once at 10 min if seizure persists)
  • └─ IF NO IV ACCESS: Midazolam 10 mg IM (or Diazepam 10 mg rectally)
  • [Time 20-40 min]: Second-Line Urgent Control (Non-Sedating IV ASMs)
  • ├─ Levetiracetam 60 mg/kg IV (max 4500 mg)
  • ├─ OR Fosphenytoin 20 mg PE/kg IV
  • └─ OR Sodium Valproate 40 mg/kg IV
  • [Time > 40 min]: Third-Line Refractory Status Epilepticus
  • ├─ Endotracheal Intubation & ICU Admission
  • └─ Continuous IV infusion: Propofol, Midazolam, or Pentobarbital with continuous EEG

Canadian Driving Regulations: Following a single unprovoked seizure or status epilepticus, patients are legally restricted from driving for at least 6 to 12 months (depending on provincial highway traffic acts) until medically cleared by a neurologist.

  • Movement Disorders
  • Parkinson's Disease (PD)

Parkinson's disease is a progressive neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum.

Cardinal Clinical Features (TRAP):

T remor: Asymmetric resting tremor ( 4 – 6 Hz 4\text{--}6\text{ Hz} 4 – 6 Hz ), classic "pill-rolling" quality, decreases with voluntary movement.

R igidity: Cogwheel or lead-pipe rigidity present on passive limb movement.

A kinesia / Bradykinesia: Slowness of movement, decreased arm swing while walking, masked facies (hypomimia), micrographia, and shuffling gait.

P ostural Instability: Loss of postural reflexes leading to falls (typically late in disease).

Pharmacotherapy:

Levodopa / Carbidopa: Most effective symptomatic therapy. Carbidopa inhibits peripheral dopa-decarboxylase, preventing peripheral conversion of levodopa to dopamine and minimizing nausea.

Dopamine Agonists (Pramipexole, Ropinirole): Preferred in younger patients ( < 60 <60 < 60 years) to delay levodopa-induced motor fluctuations and dyskinesias. Watch for side effects: Impulse control disorders (pathological gambling, hypersexuality), orthostatic hypotension, and sudden sleep attacks.

MAO-B Inhibitors (Rasagiline, Selegiline): Mild symptomatic benefit.

COMT Inhibitors (Entacapone): Used as adjunct to levodopa to prevent peripheral breakdown.

Essential Tremor

Essential tremor is the most common movement disorder, often inherited in an autosomal dominant pattern.

Key Features: Action / Postural tremor ( 8 – 12 Hz 8\text{--}12\text{ Hz} 8 – 12 Hz ) affecting the hands, arms, head ("yes-yes" or "no-no" motion), or voice. Tremor worsens during purposeful movement (e.g., holding a glass of water, writing) and improves with small ingestion of alcohol .

Treatment: First-line agents are Propranolol (non-selective beta-blocker) or Primidone (anticonvulsant).

  • Neuromuscular Disorders & Emergencies
  • Myasthenia Gravis (MG)

Myasthenia gravis is an autoimmune disorder caused by autoantibodies directed against the post-synaptic acetylcholine receptor (AChR-Ab) or muscle-specific kinase (MuSK) at the neuromuscular junction.

Clinical Presentation: Fatigurable muscle weakness that worsens with repetitive exertion and improves with rest. Initial symptoms frequently involve extraocular muscles: ptosis and diplopia. Fluctuating bulbar weakness (dysphagia, dysarthria, chewing fatigue) and proximal limb weakness follow.

Diagnostic Testing:

Anti-AChR antibody testing (highly specific).

Ice Pack Test: Application of an ice pack to a ptotic eyelid for 2 minutes improves ptosis by inhibiting acetylcholinesterase enzyme activity.

Repetitive nerve stimulation / Single-fiber EMG (shows decremental response).

Chest CT: Mandatory in all newly diagnosed MG patients to screen for thymoma (thymic hyperplasia present in 65%, thymoma in 15%).

Management:

Symptomatic treatment: Pyridostigmine (oral acetylcholinesterase inhibitor).

Chronic immunosuppression: Prednisone, Azathioprine, Mycophenolate.

Thymectomy: Indicated for thymoma or seropositive generalized MG.

Myasthenic Crisis: Life-threatening emergency characterized by severe respiratory muscle weakness causing respiratory failure. Managed in ICU with Intravenous Immunoglobulin (IVIG) or Plasma Exchange (Plex) alongside mechanical ventilation. Avoid acetylcholinesterase inhibitors during crisis to prevent excessive airway secretions.

Contraindicated Drugs: Aminoglycosides, fluoroquinolones, beta-blockers, magnesium, and neuromuscular blockers exacerbate MG.

Guillain-Barré Syndrome (GBS / AIDP)

Guillain-Barré syndrome is an acute inflammatory demyelinating polyneuropathy (AIDP) triggered by molecular mimicry following a respiratory or gastrointestinal infection (most commonly Campylobacter jejuni , CMV, or EBV).

Clinical Features: Progressive, symmetric, ascending flaccid weakness starting in the lower extremities, accompanied by areflexia or hyporeflexia. Autonomic dysfunction (arrhythmias, labile BP, paralytic ileus) and facial nerve diplegia may develop.

Diagnostic Confirmation:

Lumbar Puncture: Reveals albuminocytologic dissociation (elevated CSF protein concentration with normal CSF white blood cell count < 10 cells/ μ L <10\text{ cells/}\mu\text{L} < 10 cells/ μ L ).

Monitoring & Treatment:

Respiratory Monitoring: Serial measurements of Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) . An FVC < 20 mL/kg <20\text{ mL/kg} < 20 mL/kg or NIF < − 30 cm H 2 O < -30\text{ cm H}_2\text{O} < − 30 cm H 2 ​ O indicates impending respiratory failure requiring elective intubation.

Disease-Modifying Therapy: IVIG ( 0.4 g/kg/day 0.4\text{ g/kg/day} 0.4 g/kg/day for 5 days) or Plasma Exchange (Plex) . Both are equally effective.

Exam Trap: Corticosteroids are ineffective and strictly contraindicated in GBS.

Loading diagram... Status Epilepticus Emergency Resuscitation & Pharmacotherapy Timeline